Merck & Co Inc
NYSE:MRK 4:00:00 PM EDT
Other Pre-Announcement
Merck - Q4 2022 Worldwide Sales Were $13.8 Billion, An Increase Of 2%
Published: 02/02/2023 11:45 GMT
Merck & Co Inc (MRK) - Merck - Q4 2022 Worldwide Sales Were $13.8 Billion, an Increase of 2%.
Merck - Anticipates Full-year 2023 Worldwide Sales to Be Between $57.2 Billion and $58.7 Billion.
Merck - Q4 GAAP EPS From Continuing Operations Was $1.18; Q4 Non-GAAP EPS Was $1.62.
Merck - Expects FY GAAP EPS to Be Between $5.86 and $6.01; Expects FY Non-GAAP EPS to Be Between $6.80 and $6.95.
Merck - Qtrly Januvia/ Janumet Sales $913 Million Versus $1,393 Million.
Merck - Qtrly Gardasil/ Gardasil 9 Sales $1.47 Billion Versus $1.53 Billion.
Merck - Qtrly Keytruda Sales $5.45 Billion Versus $4.58 Billion.
Further Company Coverage: Mrkn ((reuters.
Briefs@thomsonreuters.
Com;)).
Merck - Anticipates Full-year 2023 Worldwide Sales to Be Between $57.2 Billion and $58.7 Billion.
Merck - Q4 GAAP EPS From Continuing Operations Was $1.18; Q4 Non-GAAP EPS Was $1.62.
Merck - Expects FY GAAP EPS to Be Between $5.86 and $6.01; Expects FY Non-GAAP EPS to Be Between $6.80 and $6.95.
Merck - Qtrly Januvia/ Janumet Sales $913 Million Versus $1,393 Million.
Merck - Qtrly Gardasil/ Gardasil 9 Sales $1.47 Billion Versus $1.53 Billion.
Merck - Qtrly Keytruda Sales $5.45 Billion Versus $4.58 Billion.
Further Company Coverage: Mrkn ((reuters.
Briefs@thomsonreuters.
Com;)).